Cargando…

Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial

INTRODUCTION: Xylitol (or ‘birch sugar’) is a naturally occurring sugar with antibacterial properties that has been used as a natural non-sugar sweetener in chewing gums, confectionery, toothpaste and medicines. In this preventative randomised trial, xylitol will be tested for the prevention of acut...

Descripción completa

Detalles Bibliográficos
Autores principales: Persaud, Nav, Laupacis, Andreas, Azarpazhooh, Amir, Birken, Catherine, Hoch, Jeffrey S, Isaranuwatchai, Wanrudee, Maguire, Jonathan L, Mamdani, Muhammad M, Thorpe, Kevin, Allen, Christopher, Mason, Dalah, Kowal, Christine, Bazeghi, Farnaz, Parkin, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078241/
https://www.ncbi.nlm.nih.gov/pubmed/30082349
http://dx.doi.org/10.1136/bmjopen-2017-020941
_version_ 1783345057528545280
author Persaud, Nav
Laupacis, Andreas
Azarpazhooh, Amir
Birken, Catherine
Hoch, Jeffrey S
Isaranuwatchai, Wanrudee
Maguire, Jonathan L
Mamdani, Muhammad M
Thorpe, Kevin
Allen, Christopher
Mason, Dalah
Kowal, Christine
Bazeghi, Farnaz
Parkin, Patricia
author_facet Persaud, Nav
Laupacis, Andreas
Azarpazhooh, Amir
Birken, Catherine
Hoch, Jeffrey S
Isaranuwatchai, Wanrudee
Maguire, Jonathan L
Mamdani, Muhammad M
Thorpe, Kevin
Allen, Christopher
Mason, Dalah
Kowal, Christine
Bazeghi, Farnaz
Parkin, Patricia
author_sort Persaud, Nav
collection PubMed
description INTRODUCTION: Xylitol (or ‘birch sugar’) is a naturally occurring sugar with antibacterial properties that has been used as a natural non-sugar sweetener in chewing gums, confectionery, toothpaste and medicines. In this preventative randomised trial, xylitol will be tested for the prevention of acute otitis media (AOM), a common and costly condition in young children. The primary outcome will be the incidence of AOM. Secondary outcomes will include upper respiratory tract infections (URTIs) and dental caries. METHODS AND ANALYSIS: This study will be a pragmatic, blinded (participant and parents, practitioners and analyst), two-armed superiority, placebo-controlled randomised trial with 1:1 allocation, stratified by clinical site. The trial will be conducted in the 11 primary care group practices participating in the TARGet Kids! research network in Canada. Eligible participants between the ages of 2–4 years will be randomly assigned to the intervention arm of regular xylitol syrup use or the control arm of regular sorbitol use for 6 months. We expect to recruit 236 participants, per treatment arm, to detect a 20% relative risk reduction in AOM episodes. AOM will be identified through chart review. The secondary outcomes of URTIs and dental caries will be identified through monthly phone calls with specified questions. ETHICS AND DISSEMINATION: Ethics approval from the Research Ethics Boards at the Hospital for Sick Children and St. Michael’s Hospital has been obtained for this study and also for the TARGet Kids! research network. Results will be submitted for publication to a peer-reviewed journal and will be discussed with decision makers. TRIAL REGISTRATION NUMBER: NCT03055091; Pre-results.
format Online
Article
Text
id pubmed-6078241
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-60782412018-08-09 Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial Persaud, Nav Laupacis, Andreas Azarpazhooh, Amir Birken, Catherine Hoch, Jeffrey S Isaranuwatchai, Wanrudee Maguire, Jonathan L Mamdani, Muhammad M Thorpe, Kevin Allen, Christopher Mason, Dalah Kowal, Christine Bazeghi, Farnaz Parkin, Patricia BMJ Open General practice / Family practice INTRODUCTION: Xylitol (or ‘birch sugar’) is a naturally occurring sugar with antibacterial properties that has been used as a natural non-sugar sweetener in chewing gums, confectionery, toothpaste and medicines. In this preventative randomised trial, xylitol will be tested for the prevention of acute otitis media (AOM), a common and costly condition in young children. The primary outcome will be the incidence of AOM. Secondary outcomes will include upper respiratory tract infections (URTIs) and dental caries. METHODS AND ANALYSIS: This study will be a pragmatic, blinded (participant and parents, practitioners and analyst), two-armed superiority, placebo-controlled randomised trial with 1:1 allocation, stratified by clinical site. The trial will be conducted in the 11 primary care group practices participating in the TARGet Kids! research network in Canada. Eligible participants between the ages of 2–4 years will be randomly assigned to the intervention arm of regular xylitol syrup use or the control arm of regular sorbitol use for 6 months. We expect to recruit 236 participants, per treatment arm, to detect a 20% relative risk reduction in AOM episodes. AOM will be identified through chart review. The secondary outcomes of URTIs and dental caries will be identified through monthly phone calls with specified questions. ETHICS AND DISSEMINATION: Ethics approval from the Research Ethics Boards at the Hospital for Sick Children and St. Michael’s Hospital has been obtained for this study and also for the TARGet Kids! research network. Results will be submitted for publication to a peer-reviewed journal and will be discussed with decision makers. TRIAL REGISTRATION NUMBER: NCT03055091; Pre-results. BMJ Publishing Group 2018-08-05 /pmc/articles/PMC6078241/ /pubmed/30082349 http://dx.doi.org/10.1136/bmjopen-2017-020941 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle General practice / Family practice
Persaud, Nav
Laupacis, Andreas
Azarpazhooh, Amir
Birken, Catherine
Hoch, Jeffrey S
Isaranuwatchai, Wanrudee
Maguire, Jonathan L
Mamdani, Muhammad M
Thorpe, Kevin
Allen, Christopher
Mason, Dalah
Kowal, Christine
Bazeghi, Farnaz
Parkin, Patricia
Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial
title Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial
title_full Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial
title_fullStr Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial
title_full_unstemmed Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial
title_short Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial
title_sort xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial
topic General practice / Family practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078241/
https://www.ncbi.nlm.nih.gov/pubmed/30082349
http://dx.doi.org/10.1136/bmjopen-2017-020941
work_keys_str_mv AT persaudnav xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT laupacisandreas xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT azarpazhoohamir xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT birkencatherine xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT hochjeffreys xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT isaranuwatchaiwanrudee xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT maguirejonathanl xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT mamdanimuhammadm xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT thorpekevin xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT allenchristopher xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT masondalah xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT kowalchristine xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT bazeghifarnaz xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT parkinpatricia xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial
AT xylitolforthepreventionofacuteotitismediaepisodesinchildrenaged24yearsprotocolforapragmaticrandomisedcontrolledtrial